Back to Trials
NCT06797193NARecruitingAccepts Healthy Volunteers

Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension

Mayo Clinic

Start Date

3/13/2025

Completion Date

3/31/2027

Summary

This clinical trial tests the how well an ultrasound with subharmonic imaging and the subharmonic aided pressure estimation (SHAPE) technique works in identifying portal hypertension (PH). An ultrasound takes pictures of the inside of the body by bouncing sound waves off organs. PH is high blood pressure in the vein that carries blood to the liver from the stomach, small and large intestines, spleen, pancreas, and gallbladder. The complications associated with PH are clear only after severe liver dysfunction or liver cirrhosis develops and are accompanied by relatively high mortality rates (20-70% mortality within 2 years). Thus, identifying PH earlier is beneficial. The hepatic venous pressure gradient (HVPG) obtained using an invasive catheterization procedure remains the standard for assessing PH. However, using this invasive procedure to assess PH prevents frequent pressure monitoring. Thus, a noninvasive technique to estimate PH is beneficial not only for diagnosis but also for monitoring treatment and disease progression. The SHAPE technique is a noninvasive ultrasound-based imaging technique that can estimate pressure with an ultrasound contrast agent. A noninvasive technique using an ultrasound with subharmonic imaging and the SHAPE technique may work in identifying PH.

Detailed Description

PRIMARY OBJECTIVES: I. To evaluate if SHAPE with perflutren lipid microspheres (Definity) microbubbles identifies patients with clinically significant PH. II. To evaluate if addition of subharmonic imaging-based perfusion parameters derived from time intensity curves and shear wave elastography (SWE) measurements increase the diagnostic confidence of detecting PH. OUTLINE: Patients receive Definity intravenously (IV) once on study. Additionally, patients undergo ultrasound with and without SHAPE technique as well as standard of care liver biopsy on study. After completion of study intervention, patients are followed up for 30 minutes.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Provide signed and dated informed consent form * Willing to comply with all study procedures * Adult patients (age of 18 years or older) * If a female of child-bearing potential, must have a negative pregnancy test * Be scheduled for HVPG measurement Exclusion Criteria: * Patients who are unable to provide consent * Females who are pregnant or nursing * Patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG)

Interventions

OTHER

Electronic Health Record Review

PROCEDURE

Liver Biopsy

OTHER

Medical Device Usage and Evaluation

DRUG

Perflutren Lipid Microspheres

PROCEDURE

Ultrasound Imaging

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Portal Hypertension

Locations

Mayo Clinic in Arizona

Scottsdale, Arizona 85259

United States

Mayo Clinic in Florida

Jacksonville, Florida 32224-9980

United States

Mayo Clinic in Rochester

Rochester, Minnesota 55905

United States